Post-Polycythemia Vera Myelofibrosis Treatment Pipeline Review H1 2015 Research Report Available at RnRMarketResearch.com

RnRMarketResearch.com adds “Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2015” to its store. This report provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF)’s therapeutic pipeline.

Logo

Dallas, TX -- (SBWire) -- 06/08/2015 --The report "Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects.

Complete report on Post-Polycythemia Vera Myelofibrosis (PPV-MF) with 21 market data tables and 13 figures, spread across 60 pages is available at http://www.rnrmarketresearch.com/post-polycythemia-vera-myelofibrosis-ppv-mf-pipeline-review-h1-2015-market-report.html

Companies discussed in this Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2015 report include CTI BioPharma Corp., Gilead Sciences, Inc., Incyte Corporation, Italfarmaco S.p.A., Nippon Shinyaku Co., Ltd., Novartis AG, Promedior, Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are buparlisib hydrochloride, givinostat, INCB-39110, LCL-161, NS-018, pacritinib, PRM-151, simtuzumab.

Order a purchase copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=388745

(This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2015 7
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by CTI BioPharma Corp., H1 2015 13
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences, Inc., H1 2015 14
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corporation, H1 2015 15
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco S.p.A., H1 2015 16
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 17
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H1 2015 18
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior, Inc., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Recent Pipeline Updates, H1 2015 46
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H1 2015 57
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H1 2015 58

List of Figures
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2015 7
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Explore more reports on Therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Media Relations Contact

Ritesh Tiwari
888-391-5441
http://www.rnrmarketresearch.com/post-polycythemia-vera-myelofibrosis-ppv-mf-pipeline-review-h1-2015-market-report.html

View this press release online at: http://rwire.com/603164